Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial
Authors' conclusion
In this exploratory analysis, treatment with low-dose colchicine was associated with attenuated clonal expansion in TET2 CH.
Study context
- Population
- Participants with chronic CAD2,047 observations
- Participants
- 854 participants
- Comparison
- Colchicine vs placebo
- Primary endpoint
- CH growth (annual change in CH clone size by variant allele frequency)
- Follow-up
- Median 25.0 months
Methodological detailsexploratory substudy
- Exploratory substudy
Primary result
As reported in the abstract
Annual increase in CH clone size
| Group | Value | βtime |
|---|---|---|
| Placebo | 14.9% | 0.14 (95% CI: 0.08 to 0.21) |
| Colchicine | 6.3% | 0.06 (95% CI: −0.01 to 0.14) |
Value
Placebo14.9%
Colchicine6.3%
βtime
Placebo0.14 (95% CI: 0.08 to 0.21)
Colchicine0.06 (95% CI: −0.01 to 0.14)
- Colchicine vs Placebo: P for interaction = 0.13 — not statistically significant
Further findings
Interleukin-6 increase in non-DNMT3A CH (subgroup) · 1 year
P for interaction = 0.01
| Outcome | Colchicine | Placebo | P value |
|---|---|---|---|
| Clonal growth in TET2 CH (subgroup) | P for interaction = 0.04 | ||
| βtime | 0.09 (95% CI: −0.04 to 0.22) | 0.27 (95% CI: 0.16 to 0.37) |
- Clonal growth in TET2 clonal hematopoiesis (CH) (subgroup): interaction P = 0.04
- Interleukin-6 increase in non-DNMT3A CH (subgroup): interaction P = 0.01
Original publication
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial. J Am Coll Cardiol. Published 29 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →